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Abstract
Background: Recombinant adenovirus-vectored (Ad) tuberculosis (TB) vaccine platform has demonstrated great potential
to be used either as a stand-alone or a boost vaccine in murine models. However, Ad TB vaccine remains to be evaluated in
a more relevant and sensitive guinea pig model of pulmonary TB. Many vaccine candidates shown to be effective in murine
models have subsequently failed to pass the test in guinea pig models.
Methods and Findings: Specific pathogen-free guinea pigs were immunized with BCG, AdAg85A intranasally (i.n), AdAg85A
intramuscularly (i.m), BCG boosted with AdAg85A i.n, BCG boosted with AdAg85A i.m, or treated only with saline. The
animals were then infected by a low-dose aerosol of M. tuberculosis (M.tb). At the specified times, the animals were sacrificed
and the levels of infection in the lung and spleen were assessed. In separate studies, the long-term disease outcome of
infected animals was monitored until the termination of this study. Immunization with Ad vaccine alone had minimal
beneficial effects. Immunization with BCG alone and BCG prime-Ad vaccine boost regimens significantly reduced the level
of M.tb infection in the tissues to a similar extent. However, while BCG alone prolonged the survival of infected guinea pigs,
the majority of BCG-immunized animals succumbed by 53 weeks post-M.tb challenge. In contrast, intranasal or
intramuscular Ad vaccine boosting of BCG-primed animals markedly improved the survival rate with 60% of BCG/Ad i.n- and
40% of BCG/Ad i.m-immunized guinea pigs still surviving by 74 weeks post-aerosol challenge.
Conclusions: Boosting, particularly via the intranasal mucosal route, with AdAg85A vaccine is able to significantly enhance
the long-term survival of BCG-primed guinea pigs following pulmonary M.tb challenge. Our results thus support further
evaluation of this viral-vectored TB vaccine in clinical trials.
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Introduction
Pulmonary tuberculosis (TB) has remained one of the leading
infectious causes of death world-wide. BCG (Bacille Calmette-
Guerin) has been used in human immunization programs as the
only TB vaccine since 1921. However, while BCG is effective in
protecting from severe or disseminated forms of childhood TB, it
fails to effectively protect against adult pulmonary TB [1–3]. This
may be due, in part, to the fact that BCG is administered in most
countries shortly after birth but BCG-triggered protective T cell
immunity diminishes markedly in 10–15 years. Thus, TB vaccine
development efforts may need to focus more on the development
of booster vaccines that can effectively enhance and extend
immunity triggered by primary immunization with BCG or an
improved BCG vaccine [4]. In this regard, it is now clear that
BCG vaccine itself cannot be used as an effective boost vaccine
[5,6] and in fact, some experimental studies have indicated that
BCG boosting of BCG-primed animals can be even deleterious
[7,8]. This suggests that effective booster vaccine candidates ought
to be non-mycobacterial organism-based or heterologous to BCG
in nature.
There are three major types of heterologous boost vaccine
candidates: protein-, plasmid DNA- and viral-based vaccines. To
adequately assess these vaccine candidates for their respective
potential to be used for boosting purposes, a two-stage evaluation
process is usually undertaken. First, they are evaluated as stand-
alone vaccines for their relative immunogenicity and protective
efficacy. Once the proof of principle is established, the selected
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protocols where BCG is used as a prime vaccine. The most
commonly utilized animal species for such evaluations is the
mouse due to its inexpensive nature and the availability of
abundant immunologic reagents. However, compared to murine
models, the guinea pig model is much more sensitive to pulmonary
M.tb infection, thus representing a stringent animal model for
further selection of promising vaccine candidates prior to their
evaluation in humans [9].
We were the first to have developed a recombinant, replication-
defective human type 5 adenovirus (Ad)-vectored TB vaccine
expressing an immunodominant M.tb antigen Ag85A (AdAg85A)
[10,11]. We demonstrated that a single intranasal, but not
intramuscular, vaccination with AdAg85A in a mouse model
provided a level of protection against pulmonary M.tb challenge
that was comparable to or even better than that by standard s.c
BCG vaccination [10]. Such enhanced protection by mucosal
immunization was mediated by persisting airway luminal T cells
[12,13]. We further demonstrated that intranasal mucosal
boosting with AdAg85A enhanced protective immunity much
more significantly than intramuscular boosting in BCG-primed
mice [14]. While these murine data are encouraging, it remains
unclear whether AdAg85A will be effective in guinea pig models.
In our current study we have evaluated the efficacy of AdAg85A
either as a primary or as a booster vaccine for BCG prime
immunization in a stringent guinea pig model of pulmonary
tuberculosis. We have also compared the relative efficacy by
intranasal and intramuscular routes of immunization.
Methods
Animals
Outbred, specific pathogen-free guinea pigs of the Hartley strain
(about 250–300 g) were purchased from Charles River Breeding
Laboratories, Inc., Wilmington, MA, individually housed and
maintained in a standard temperature, humidity and light-
controlled environment. All of the procedures were approved by
the Texas A&M University Institutional Animal Care and Use
Committee.
Vaccines and immunization regimens
A dose of 10
3 cfu of Danish strain of BCG (BCG 1331) was
injected i.d to each guinea pig for BCG immunization. A
recombinant, replication-defective human type 5 adenovirus
expressing M.tb Ag85A (AdAg85A) was developed and extensively
evaluated in both murine and bovine models of pulmonary
tuberculosis as previously described [10,12–16]. A dose of 10
8 pfu
of AdAg85A was inoculated either i.m or i.n to naı ¨ve or BCG-
primed guinea pigs. The choice of this dose was supported by pilot
short-term survival studies where several doses of AdAg85A
ranging from 10
5 to 10
8 pfu/guinea pig were tested and the
10
8 pfu dose appeared to slightly better protect guinea pigs over
the saline control or lower dose groups. Prior to inoculation,
animals were lightly anesthetized i.m with a mixture of ketamine
and xylazine (7.5 mg/kg and 0.625 mg/kg, respectively). For i.n
delivery, 25 ml of diluted virus vaccine was administered to each
nare for inhalational inoculation.
For short-term studies, groups of five guinea pigs were set up as
naı ¨ve, BCG, AdAg85A i.n, AdAg85A i.m, BCG prime/AdAg85A
i.n boost, and BCG prime/AdAg85A i.m boost. The booster was
givenat 4 weekspost-BCG priming.Allguineapigs werechallenged
with M.tb at 10 weeks from the point of initial immunization and
euthanized humanely for cfu assay at 40 days post-M.tb challenge
(Fig. 1A diagram). For long-term disease outcome studies, groups of
eight guinea pigs were set up as exactly as for the above short-term
studies except that the guinea pigs were not euthanized at 40 days
post-M.tb challenge and were euthanized only when they reached
the clinical disease endpoint or at the termination of study at 74
weeks post-challenge (Fig. 1B diagram).
Pulmonary M.tb challenge
Both unimmunized and immunized guinea pigs were infected
with a low dose (10
5 cfu in the nebulizer to result in 10–15 cfu
implanted to each animal) of virulent M.tb H37Rv (ATCC 27294)
via the respiratory route by aerosol as previously described [17]. A
Madison chamber (University of Wisconsin Engineering Shops,
Madison, WI) was used for aerosol generation and calibrated for
low dose delivery to the lung.
Experimental endpoints
For short term studies, all guinea pigs were euthanized at 40 days
post-M.tb challenge as described above. For long-term disease
outcome studies, the animals were weighed prior to aerosol M.tb
challenge and weighed weekly beginning at 10 weeks post-
challenge. Determination of euthanasia was made by using a
modified Karnovsky disease scoring method taking into account
both significant body weight loss and the overall health condition of
the animals including their respiratory rate, general behavior and
physical appearance [17,18]. Animals that demonstrated constant
signsof disease progression were euthanized byi.p. injectionwith an
overdose of sodium pentobarbital (Sleepway Euthanasia Solution,
Fort Dodge, IA). Cardiac blood was removed using a heparinized
syringe and sera were prepared and stored at 220 degrees.
Tissue processing and bacterial colony formation assay
The lungs and spleens were removed aseptically. The right
lower lobe of the lung and the 2/3’s of the spleen were processed
for mycobacterial colony formation assay as previously described
[17,18]. Briefly, tissues were homogenized in 4.5 mls of saline
buffer and serial dilutions were plated in duplicate onto 7H10
Middlebrook agar plates and incubated in an incubator at 37uC
for 21 days for cfu determination.
Data analysis
The log rank analysis was carried out to determine the
difference in survival between various treatments. Other data
Figure 1. Experimental regimens used for both short-term and
long-term guinea pig studies.
doi:10.1371/journal.pone.0005856.g001
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hoc tests. The difference was considered statistically significant
when p#0.05.
Results
Effects of BCG priming and Ad boosting on tissue
bacterial counts
To investigate the impact of various immunization regimens on
the level of M.tb infection, guinea pigs were primed first i.d with
BCG and subsequently boosted either intranasally (i.n) or
intramuscularly (i.m) with AdAg85A vaccine (Fig. 1A). The
control animals were treated only with saline (0.8%) or BCG.
The animals were then challenged by M.tb aerosol at 6 weeks post-
boosting. The level of mycobacterial infection was assessed both in
the lung and spleen 40 days after challenge. Consistent with the
previous reports, BCG alone significantly reduced bacterial
burden both in the lung and spleen (Fig. 2A/B; p=0.004 and
p=0.002 compared to saline control, respectively). In comparison,
i.n or i.m with Ad vaccine alone did not reduce the level of
infection in these tissues (data not shown). While immunization by
BCG prime/Ad boost i.n or i.m only moderately reduced bacterial
burden in the lung (Fig. 2A; p=0.05 and p=0.08 compared to
saline, respectively), it markedly reduced bacterial counts in the
spleen (p=0.002 and p=0.002 compared to saline, respectively),
being even slightly better than BCG alone (Fig. 2B).
Effects of BCG priming and Ad boosting on long-term
disease outcome
As the bacterial loads in the tissue of guinea pig models may not
adequately predict the protective efficacy of a test vaccine [19], in
separate studies the long-term disease outcome was monitored
following immunization and low dose M.tb aerosol challenge in a
separate study. By the end of first 10 weeks post-infection,
unimmunized guinea pigs already began to display deteriorating
overall health conditions including much lower average body
weight compared to the immunized groups (Fig. 3; BCG
p=0.008, BCG/Ad i.n p=0.006 and BCG/Ad i.m p=0.03
compared to saline control).
Between weeks 10 and 30 post-infection, the overall body
conditions of unimmunized guinea pigs continued to deteriorate,
resulting in greater than 80% mortality and, by week 60, all of the
non-vaccinated guinea pigs succumbed (Fig. 4). Although the
deterioration of health conditions of guinea pigs immunized i.n or
i.m with AdAg85A vaccine alone somewhat lagged behind the
saline group, the difference does not appear strikingly significant
between these groups (data not shown; also see Fig. 5). In contrast,
the majority of guinea pigs immunized with BCG, BCG/Ad i.n or
BCG/Ad i.m remained healthy up to week 40 (Fig. 4; p=0.0007
compared to saline control). However, by week 45, about 50% of
BCG-immunized guinea pigs succumbed whereas the majority of
BCG-vaccinated guinea pigs boosted i.n or i.m with AdAg85A
vaccine remained healthy (Fig. 4). Throughout the course of study
and until the point of study termination, the BCG-vaccinated
guinea pigs boosted i.n with AdAg85A vaccine appeared to
perform better than those boosted i.m with AdAg85A vaccine,
although the difference was not statistically significant (Fig. 4).
Between weeks 45 and 55, the majority of guinea pigs immunized
with BCG alone also succumbed (Fig. 4). Thus, by the time when
the study was terminated (74 weeks post-challenge), only about
10% of BCG-immunized guinea pigs were still alive. In contrast,
more than 60% of BCG/Ad i.n- and 40% of BCG/Ad i.m-
immunized animals were still living (Fig. 4; p=0.03 BCG/Ad i.n
compared to BCG alone; p=0.1 BCG/Ad i.m compared to BCG
alone).
Figure 2. Levels of M.tb bacterial counts in the lung and spleen.
The guinea pigs were treated as depicted in Fig. 1A and bacterial
counts in the lung (A) and spleen (B) were determined at five and half
weeks post-M.tb challenge by a colony formation assay. Results are
expressed as means6SEM of five animals per group. **p#0.01, *p#0.05
compared to saline control.
doi:10.1371/journal.pone.0005856.g002
Figure 3. Comparison of average body weight changes at ten
weeks post-M.tb challenge. Groups of guinea pigs were treated as
depicted in Fig. 1B and body weight changes were monitored on a
weekly basis. The data are the average body weight6SEM of each
treatment group (eight animals per group) recorded at 10 weeks post-
M.tb challenge prior to the occurrence of mortality in any treatment
groups. **p#0.01, *p#0.05 compared to saline control.
doi:10.1371/journal.pone.0005856.g003
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Death
We further calculated the Mean Days to Death (MDD) for each
treatment group. On average, unimmunized animals survived an
average of 177 days whereas Ad i.n alone and Ad i.m alone only
moderately enhanced the mean survival time to 229 and 192 days,
respectively (Fig. 5). In comparison, BCG immunization alone
increased the survival time to 308 days (p=0.02 compared to
saline group). AdAg85A vaccine i.n and i.m boosting to BCG-
immunized animals further significantly enhanced it to 467 and
412 days, respectively although the differences between BCG and
BCG/Ad i.m groups did not reach statistical significance (Fig. 5;
p=0.02 BCG/Ad i.n compared to BCG alone; p=0.12 BCG/Ad
i.m compared to BCG alone). It is noteworthy that the MDD for
Ad vaccine boost groups are very likely underestimated since at the
time of study termination, as a significant proportion of animals in
Ad vaccine-boosted groups were still surviving (60% and 40% for
BCG/Ad i.n and BCG/Ad i.m groups, respectively). Thus, clearly
Ad vaccine boosting markedly improved the survival rate of BCG-
primed guinea pigs.
Discussion
The adenoviral vector is a promising vaccine platform for
mucosal infectious diseases including pulmonary TB as it can be
effectively administered via either the parenteral or mucosal route.
[20,21]. However, mounting evidence suggests that the mucosal
route of vaccination is superior to parenteral vaccination in
protecting mucosal surfaces [21]. Indeed, we have previously shown
that a single respiratory mucosal dose of an adenovirus-vectored
Figure 4. Kaplan-Meier curves of percent survival of M.tb-infected guinea pigs over the course of 74 weeks post-challenge. Groups of
guinea pigs (eight animals per group) were treated as depicted in Fig. 1B and their survival rate was determined on a weekly basis up to 74 weeks
when the entire study was terminated. p#0.01 BCG, BCG/Ad i.n and BCG/Ad i.m compared to saline control; p#0.05 BCG vs. BCG/Ad i.n; p#0.1 BCG
vs. BCG/Ad i.m.
doi:10.1371/journal.pone.0005856.g004
Figure 5. Comparison of Mean Days to Death of various treatment groups of guinea pigs. Mean Days to Death (MDD) was determined by
dividing the summed total number of surviving days of each treatment group with the number of animals/group. Results are expressed as
means6SEM of eight animals/group. Note: MDD for BCG/Ad groups may have been underestimated as 40–60% of animals in these treatment groups
were still surviving at the time study termination (74 weeks). **p#0.01, *p#0.05 compared to saline control or between BCG and BCG/Ad i.n.
doi:10.1371/journal.pone.0005856.g005
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Ag85A (AdAg85A) provided robust protection against pulmonary
tuberculosis which could be even better than BCG vaccination in a
murine model of pulmonary tuberculosis [10]. Furthermore, we
have demonstrated that respiratory mucosal delivery, but not
intramuscular delivery, of AdAg85A remarkably enhanced protec-
tive immunity in BCG-primed mice [14]. However, whether this
vaccine is effective in a more stringent guinea pig model has
remained unclear.Investigating TBvaccinesinguinea pigmodelsof
TB represents an important step in TB vaccine development as a
vast majority of vaccine candidates shown to be effective in murine
models have failed to pass the test in guinea pig models and are
hence considered unsuitable for further evaluation in clinical trials
[19]. This realization has prompted us to evaluate the efficacy of
AdAg85A either as a primary or as a boost vaccine for BCG prime
immunization in a guinea pig model of pulmonary tuberculosis. We
have observed that while immunization with AdAg85A vaccine
alone did not significantly improve the survival of infected guinea
pigs, intranasal or intramuscular boosting with AdAg85A markedly
improved the survival rate of BCG-primed animals over that by
BCG immunization alone. Furthermore, intranasal boosting with
AdAg85A appeared to be more robust than intramuscular boosting.
In contrast to our previous observations made in the mouse
[10,12], a single primary immunization with AdAg85A in guinea
pigs, even via the intranasal route, failed to provide significantly
enhanced protection. This is not entirely unexpected as guinea
pigs are extremely susceptible to M.tb infection and many
promising stand-alone candidate vaccines of genetic nature have
failed to protect in guinea pig models [19]. As it is believed that
BCG will continue to be used as a primary vaccine for human
immunization and that effective boost vaccines need to be
identified, our current finding that Ad vaccine-based boosting is
effective to improve protection to BCG-primed guinea pigs, is
significant. To date, only a very few candidate vaccines or
vaccination strategies were found to be able to further improve the
survival of infected guinea pigs over that by BCG immunization
alone. These include a regimen of BCG prime and two repeated
heterologous virus boost immunizations (MVAAg85A and
FPAg85A) [19,22], and co-injection of an adjuvanted polyprotein
Mtb72F vaccine with BCG [23]. Based on these encouraging data
from guinea pig models, both MVAAg85A and Mtb72F are under
further evaluation in clinical trials [3,24]. Of note, compared to
MVAAg85A viral TB vaccine, our AdAg85A vaccine seems to be
more potent in protecting infected guinea pigs as the former, when
used as a standalone boost vaccine, failed to further enhance the
survival of BCG-primed guinea pigs [19]. The robust boosting
effect of AdAg85A delivery in prior BCG-primed animals is likely
attributed to potent Ad-driven production of immunodominant
M.tb antigen Ag85A and strong immune adjuvanticity of
adenoviral backbone [11,20,21]. Indeed, the human type 5
adenovirus-based vector remains to be the most powerful gene
transfer vehicle [20].
Previous studies have suggested that quantitative estimates of
the bacterial burden in the tissues of guinea pigs may not be a
reliable indicator of the protective efficacy of some TB vaccines,
and that long-term disease outcome may be a more relevant
readout of protective efficacy for such vaccines [19,23,25] Indeed,
in our current study we observed very small differences in bacterial
counts between BCG alone, BCG/Ad i.n boost and BCG/Ad i.m
boost groups while BCG/Ad vaccine boost, particularly BCG/Ad
i.n boost, markedly enhanced the survival of infected guinea pigs
over that by BCG immunization alone.
Our previous study carried out in murine models has shown
that intranasal, but not intramuscular, boosting with AdAg85A
could dramatically further enhance protection in BCG-primed
mice [14]. This represents yet another important difference
between murine and guinea pig models as in our present study
we have shown both intranasal and intramuscular boosting is
effective in protracting the survival of BCG-primed guinea pigs
although intranasal boosting appears to be more potent than
intramuscular boosting (greater than 60% survival by i.n boosting
vs 40% by i.m boosting at 74 weeks post-challenge). In fact, this
finding is consistent with our recent cattle studies where parenteral
AdAg85A boosting was found to be effective not only in enhancing
memory T cell responses triggered by BCG priming [15] but also
in enhancing protection from pulmonary tuberculosis (unpub-
lished study). Together these findings from both guinea pig and
bovine models raise the hope that parenteral boosting with virus-
based TB vaccine will be sufficient to enhance protective
immunity in previously BCG-vaccinated humans. Admittedly,
the intervals between BCG priming and viral boosting in
experimental animal models have been from one month to 3
months given practical considerations and a short life-span of
animals, which cannot replicate what is expected to happen in
human immunization program. In humans, we believe that an
effective TB booster shall be given at least once at the time of
adolescence since BCG-triggered protective immunity usually
wanes 10–15 years after neonatal BCG vaccination [2].
Our current study represents the first to have compared side-by-
side the effects of mucosal (intranasal) and parenteral (intramus-
cular) routes of booster immunization in the guinea pig. The fact
that intranasal route of boost immunization with a recombinant
virus-based TB vaccine appears to be more effective than the
intramuscular route, further supports the general conclusion from
our previous murine studies that respiratory mucosal vaccination is
more effective than parenteral vaccination particularly when a
genetic-based vaccine vector is used [2]. Our previous studies have
demonstrated that intranasal delivery of recombinant adenoviral
gene transfer vector primarily targets the epithelial cells of
conducting airways and alveoli and to a lesser extent, alveolar
macrophages [26,27]. It is very likely that M.tb antigens secreted
by infected epithelial cells and macrophages can be picked up by
dendritic cells located within and beneath the epithelium. Infected
macrophages may also turn into dendritic cells. The M.tb antigen-
laiden dendritic cells thus can go on to activate T cells in the lung
draining lymphoid tissues [28]. In murine models, the superiority
of intranasal vaccination is attributed to the elicitation of long-
lasting respiratory airway luminal antigen-specific T cells,
particularly cytotoxic, IFN-c-producing CD8 T cells [12,13].
Due to the lack of immunological reagents for guinea pigs, we
could not investigate whether this is also the case in intranasally
AdAg85A-boosted guinea pigs. However, we speculate that a
similar mechanism may be operating in these animals.
The last several years have seen a small number of promising
candidate vaccines entering early phase of clinical trials [3,24].
Among these vaccines are modified BCG vaccines, fusion protein
vaccines and recombinant viral-vectored vaccines. A modified
vaccinia Ankara viral vaccine (MVAAg85A) is the only candidate
vaccine that has completed several phase I clinical studies and
entered a phase II trial [29]. It is now widely accepted that it is
imperative to have multiple promising TB vaccine candidates
evaluated in early-phase human studies since in spite of the result
from preclinical evaluation, the final verdict regarding the
suitability of any vaccine candidate for mass human immunization
program cannot be reached until it is evaluated in late phase,
large-scale field trials. Thus, with the encouraging results from
small to large-size animal studies, AdAg85A vaccine is about to be
evaluated in a phase I clinical trial in Canada [30].
BCG Prime-Virus Boost
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